SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) November 20, 2003
INCARA PHARMACEUTICALS CORPORATION
(Exact name of registrant as specified in its charter)
| Delaware | 0-27410 | 56-1924222 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer ID Number) |
| P.O. Box 14287 79 T. W. Alexander Drive 4401 Research Commons, Suite 200 Research Triangle Park, North Carolina |
27709 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code (919) 558-8688
| Item 5. | Other Events and Regulation FD Disclosure |
On November 20, 2003, Incara Pharmaceuticals Corporation issued a press release announcing that its stockholders approved its corporate reorganization. A copy of this press release is attached as an exhibit.
| Item 7. | Financial Statements and Exhibits |
| (c) | Exhibits |
| Exhibit 99.1 | Press release dated November 20, 2003 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.
| INCARA PHARMACEUTICALS CORPORATION | ||||
| Date: November 20, 2003 |
||||
| /s/ Richard W. Reichow | ||||
| Richard W. Reichow Executive Vice President and Chief Financial Officer | ||||